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Multiple sclerosisis a quantitative parameter that characterizes the morphometric variability of a
complex object. Among other applications, FD has been used to identify abnormalities of the human brain in
conventional magnetic resonance imaging (MRI), including white matter abnormalities in patients with
Multiple Sclerosis (MS). Extensive grey matter (GM) pathology has been recently identiﬁed in MS and it
appears to be a key factor in long-term disability. The aim of the present work was to assess whether FD
measurement of GM in T1 MRI sequences can identify GM abnormalities in patients with MS in the early
phase of the disease. A voxel-based morphometry approach optimized for MS was used to obtain the
segmented brain, where we later calculated the three-dimensional FD of the GM in MS patients and healthy
controls. We found that patients with MS had a signiﬁcant increase in the FD of the GM compared to controls.
Such differences were present even in patients with short disease durations, including patients with ﬁrst
attacks of MS. In addition, the FD of the GM correlated with T1 and T2 lesion load, but not with GM atrophy
or disability. The FD abnormalities of the GM here detected differed from the previously published FD of the
white matter in MS, suggesting that different pathological processes were taking place in each structure.
These results indicate that GM morphology is abnormal in patients with MS and that this alteration appears
early in the course of the disease.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Multiple Sclerosis (MS) is a chronic inﬂammatory and neurode-
generative disease of the central nervous system [1]. Although lesions
involving the white matter (WM) are well recognized, recent studies
have indicated extensive damage of the grey matter (GM) in MS,
including microglia activation, cortical demyelination, and axonal,
synaptic, and neuronal loss [2–7]. Recently, the extension and patho-
logical basis of GM pathology have been highlighted from pathological
and neuroimaging studies [8]. GM atrophy, extensively reported in
MS, begins early and evolves over the course of the disease, and
GM tissue volumes are lower in MS patients than in control subjects
[9–15]. The study of GM damage is of critical importance since axonal
and neuronal damage are the main factors responsible for long-term
disability in MS.Biology; Systems Biology Unit;
of Jaén; Campus Las Lagunillas
3211875.
l rights reserved.
Fractal dimension analysis ofNeuroimaging studies have identiﬁed abnormalities in the GM of
patients with MS, mainly volumetric changes. There are different
approaches for detecting and quantifying the subtle neuropathologi-
cal alterations taking place in the brain tissue inMS patients, including
the magnetization-transfer ratio, diffusion-weighted imaging, or
magnetic-resonance spectroscopy [16]. Recently, we found that fractal
dimension (FD) identiﬁes changes in theWMofMS patients, including
the normal-appearing WM, even at the early stage of the disease [17].
FD is a measurement of the topological complexity of an object [18],
and thus changes in the FD indicate alterations in the tissue structure
under study. Because the WM has a highly complex anatomy such as
the presence of axonal bundles, a pathological process that destroys
brain tissue by creating an amorphous glial scar would decrease the
FD of this tissue, as was the case of WM in MS [17]. Thus, FD can serve
as a surrogate marker of the degree of brain damage.
The aim of the present studywas to assess the FD of GM in healthy
individuals and MS patients. Here, we focus primarily on patients
at the early to intermediate phases of the disease in order to iden-
tify whether FD changes are an early phenomena in the disease
course. For this goal, we developed a new computational algorithmgrey matter in multiple sclerosis, J Neurol Sci (2009), doi:10.1016/j.
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instead of using overlapping 2D images or creating a pseudo-3D
analysis.
2. Materials and methods
2.1. Patients
A total of 52 patients with MS and 20 gender- and age-matched
healthy controls were recruited by their neurologist (PV). All subjects
gave their written informed consent according to the Helsinki
Declaration before being included in the study, which was approved
by the local Research Ethics Committee. Twenty patients suffered ﬁrst
attacks of MS (FAMS), fulﬁlling the criteria of dissemination in space
and time [19]; and 32 had relapsing–remitting MS (RRMS). Patients
with an active relapse, or who were taking corticosteroids or who had
suffered a clinical relapse within the previous two months were
excluded. MS-related disability was clinically assessed using the
Extended Disability Status Scale (EDSS) [20] and the MS Functional
Composite (MSFC) [21]. Demographic, clinical and MR image data of
the subjects are shown in Table 1.
2.2. MR acquisition
In the following month of neurological assessment, a MR imaging
study was performed on a 1.5-T SIEMENS SYMPHONY scanner
(Erlangen, Germany). High-resolution volumetric images were
acquired with a T1-weighted MR sequence (TR 2140 ms, TE 5.04 ms,
ﬂip angle 15°; 256×256 matrix size; 48 contiguous 3-mm axial slices;
25-cm FOV; in-plane resolution of 0.5×0.5) and a proton density/T2-
weighted sequence (TR 3700 ms, TE 29 ms, turbo factor 5; 256×256
matrix size; 48 contiguous 3-mm axial slices; 25-cm FOV; in-plane
resolution of 0.5×0.5).
2.3. Brain segmentation and volume of lesions
A modiﬁed version of the optimized voxel-based morphometric
(VBM) protocol [22] was used by a trained operator (JS) in order to
obtain the normalized and segmented GM images from each subject's
T1 MR, while avoiding the bias introduced by WM lesions in the
normalization and segmentation procedures [23]. For this purpose we
used SPM2 toolbox (Wellcome Department of Cognitive Neurology,
University College of London, London, UK), www.ﬁl.ion.ucl.ac.uk/spm
running under Matlab v. 6.5 (Mathworks Inc., Natick, MA), and MRIcro
software (Chris Rorden, University of Nottingham, Great Britain;
http://www.sph.sc.edu/comd/rorden/mricro.html). In brief, a 3D
binary MS lesion mask in native space was created at the voxel level
for each patient (intra-class correlation coefﬁcient=0.892 (pb0.001)Table 1
Baseline demographics of the MS patients and HC group
MS HC p value
N 52 20
Agea 35.27±8.82 37.35±8.66 ns
Sex ratio, male:female 16/36 8/12 ns
Disease durationb, years 2.20 (1 to 36) na
MS subtype 20 FAMS/32 RRMS na
EDSSb 2.0 (0 to 6.0) na
MSFCa 0.15±0.73 na
T1 lesion loadb, cm3 7.90 (0.1 to 96.41) na
T2 lesion loadb, cm3 36.84 (1.20 to 175.90) na
GM volumea, cm3 522.67±52.33 633.87±72.41 b0.001
HC: Healthy control; MS: Multiple Sclerosis; CIS: Clinically Isolated Syndrome; RR:
Relapsing–Remitting; EDSS: Expanded Disability Status; MSFC: MS Functional
Composite; GM: grey matter. Data are expressed in amean±standard deviation or
bmedian (range) depending on the distribution of the variable. na: Not applicable. ns:
Not statistically signiﬁcant.
Please cite this article as: Esteban FJ, et al, Fractal dimension analysis of
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lesions in every segmentation and normalization step in the VBM
protocol [23]. In order to preserve the total within-voxel volume, all
voxel signal intensities in the ﬁnal GM segmented images were
multiplied by the Jacobian determinants (Jacobian modulation)
derived from the spatial normalization [22]. For each patient, we
also measured the total volume of WM-lesion load on T1 and T2
studies using the MRIcro software. We calculated the total lesion
volume in each patient by multiplying the total number of lesion
voxels by the size of the voxel.
2.4. 3D fractal dimension computation method
The FD of the entire brain was determined from segmented GM in
each subject. We selected the classical box-counting method [24] for
computing the 3D-FD values because it can evaluate the FD of
structures without self-similarity (the brain is not strictly self-similar;
[25]). To achieve this, the corresponding 156 2D-MR images for each
subject were stored in a 3D grid where each position (X, Y, Z) is the
value between 1 and 255 for the pixel (X, Y) in the given image Z.
These types of grids are typically referred to as 3D images or volumes
[26]. For each box of size N, we construct 3D boxes by collecting N+1
consecutive pixels in the three dimensions of the grid. If all pixels
located inside a box have a value greater than or equal to the speciﬁed
threshold (see below), then the box is classiﬁed as BLACK; if the value
of the pixels is lower than the speciﬁed threshold, then the box is
classiﬁed as WHITE; otherwise, the box is classiﬁed as GREY (Fig. 1).
Then, for each case of study and threshold, we classiﬁed boxes with
sizes between 1 and 50, where the corresponding BLACK+GREY data
constituted the basis for calculating the 3D-FD. The 3D-FD values were
obtained through a log–log linear regression in which the X axis
represents the inverse of the size of the boxes and the Y axis
represents the box counting for the type of box selected. The ﬁnal
value for the 3D-FD corresponds to the slope of this linear regression
for the range of box sizes that maximizes the correlation value for the
given threshold (Fig. 1). A previous manual segmentation of the
images using ImageJ (http://rsbweb.nih.gov/ij/) showed 70 as the
most appropriate threshold value (in a grey scale from 0 to 255); thus,
the 3D-FD values ﬁnally obtained from each subject for the statistical
analysiswere thosewith 70 as the segmentation threshold, and from6
to 16 as the range of box sizes (which maximizes the correlation for
this threshold; Fig. 1).
The accuracy of our method for 3D-FD calculation was determined
by evaluating three different 3D objects withwell-known dimensions:
a solid cube of size 320×320×320 (exact topological dimension: 3), a
solid sphere of diameter 320 (exact topological dimension: 3), and the
Menger Sponge of size 320×320×320 (exact fractal dimension:
2.7268). The 3D-FD values resulting with our approach were 2.9876,
2.9428, and 2.725, respectively; these results are very close to the
theoretical values and similar to those detected using other published
approaches to calculate the FD of cerebral structures [25,27].
The 3D grid generated from segmented 2D MRI slices, 3D box
counting, 3D visualization and the 3D-FD computation and graphical
representation has been implemented in C++ language, and OpenGL
library [28] was used for the graphical output. Other modules of our
software performed the batch processes for computing the several
3D-FD for different box size ranges and thresholds over the collection
of subjects. Finally, the results of the batch processes were stored in
tab-delimited text ﬁles.
2.5. Statistical analysis
We used the Shapiro–Wilk test to determine the normal distribu-
tion of our variables and the Kruskal–Wallis and Mann–Whitney W
test to compare the FD values between groups of subjects. Pearson's or
Spearman's correlation tests (parametric and non-parametric,grey matter in multiple sclerosis, J Neurol Sci (2009), doi:10.1016/j.
3F.J. Esteban et al. / Journal of the Neurological Sciences xxx (2009) xxx–xxx
ARTICLE IN PRESSrespectively) were applied to assess univariate correlation depending
on the distribution of the variables. The level of signiﬁcance for the
results was set at p=0.05. These analyses were carried out using the
statistical packages SPSS v13.0, or STATGRAPHICS Plus 5.1.
3. Results
We quantiﬁed the FD of the GM in a cohort of 52 patients with MS
and 20 controls, using a new computational method for calculating
the 3D-FD. Clinical demographics are shown in Table 1. The cohort was
comprised of patients in the early to intermediate stages of the disease
(FAMS: n=20; RRMS: n=32), except for one patient with long disease
duration (36 years). In addition, patients had low to signiﬁcant
disability (median EDSS 2.0 [range: 0 to 6.0]). After calculating the 3D-
FD of the brain GM from each subject, we found that patients with MS
had an increase in the FD of the GM compared to controls (MS FD:
2.67959±0.00103; controls FD: 2.67146±0.00144; pb0.001; Fig. 2A).
Such differences in the FD of the GM were found for either FAMS or
RRMS compared to controls (FAMS FD: 2.676±0.0017; RRMS FD:Fig. 2. Fractal dimension (FD) comparison of the grey matter (GM) corresponding to the
full-range thresholded images from controls and patients. A) Patients with MS have
higher FD of the cortical GM than healthy controls (HC). B) Comparison of the FD
analysis between disease subtype and HC. Results are expressed as the mean (x) and
SEM (bars) of the FD.
Fig. 1. Grid classiﬁcation for a 3D image composed of 156 2D slices of segmented grey
matterwith a threshold of 1 and for twodifferent box sizes: 2 (A) and 5 (B); due to the 3D
representation, all boxes shown are classiﬁed as GREY. Boxes of sizes 2 (C) and 5 (D) for
only one row of the total classiﬁcation, where the box classiﬁcation in BLACK (blue
colour), WHITE (empty colour) and GREY (green colour) is clearly shown. (E) Example of
3D fractal dimension computation through linear regression over the box counting; the
range selected for the linear regression is the set of green points (box sizes from 6 to 16);
red points are the box counting of box sizes not selected for the ﬁnal computation.
Please cite this article as: Esteban FJ, et al, Fractal dimension analysis of
jns.2008.12.0232.681±0.0011) (pb0.05 in both cases; Fig. 2B). Finally, we also found a
signiﬁcant difference in the GM FD between FAMS and RRMS patients
(pb0.05; Fig. 2B).
Concerning the brain-lesion load, we found a statistically sig-
niﬁcant correlation between the FD of the GM and lesion volume, both
on T1 (r=0.435, p=0.005) and T2 (r=0.329, p=0.017). On the other
hand, the FD of the GM did not correlate with GM volume. Also, we
investigated whether the changes in the FD would be associated with
clinical variables. No correlation was detected between the FD of the
grey matter and EDSS, MSFC scores, disease duration, or age (data not
shown).
4. Discussion
In this study, we applied a new technique for analyzing GM
pathology in MS, i.e. 3D-FD. Our results of higher FD values of the GM
in MS patients compared to controls indicate that GM tissue in MS has
higher morphological complexity, perhaps due to the presence of the
inﬂammatory component (i.e. microglia activation) and cellular
changes (synapse pruning, demyelination, brain-blood barrier
changes, etc.) in the GM. This ﬁnding is striking because in our
previous study assessing the FD of the WM, we found a decrease
instead of an increase in the FD of the WM in MS patients [17]. This
differential behavior in the FD between GM and WM in MS supports
the concept that the damage mechanism or the response to tissue
damage differs between GM and WM. Similar ﬁndings have been
reported for other techniques studying GM inMS, such as GM atrophy,
which was found to follow different dynamics between GM and WM
in MS [15]. GM damage is of particular importance in MS, because
tissue damage in GM is a large component of MS disease load and a
key factor in long-term disability. Measurement of GM atrophy is a
sensitive technique for identifying lesions in GM, as well as other non-
conventional MRI techniques (MRS, DTI, MTR), when compared to the
insensitivity of conventional MRI techniques (T1, T2, PD) for identify-
ing GM damage [15,29]. Therefore, new methods able to quantify GM
pathology would be very important for monitoring disease course.grey matter in multiple sclerosis, J Neurol Sci (2009), doi:10.1016/j.
4 F.J. Esteban et al. / Journal of the Neurological Sciences xxx (2009) xxx–xxx
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detect GM changes in the cerebral architecture, providing an overall
measurement of anatomical changes due to MS, as previously shown
at the WM level [17].
Abnormalities in GM in MS appear from the clinical onset of the
disease and become more pronounced as the condition progresses
[16]. Our study has been carried out including mainly patients with a
short to medium course of the disease (FAMS and RRMS patients).
Thus, our study indicates that FD of the GM can detect subtle changes
already present in the early stages of the disease. The fact that
differences increased from FAMS to RRMS also suggests that FD
changes increase with disease evolution. However, we cannot predict
the behavior of the FD of the GM in progressive patients because GM
atrophy is highly prominent in this subgroup of patients and can
inﬂuence the calculation of the FD. Future studies in patients with
progressive disease together with longitudinal studies assessing the
FD of the GM will clarify whether FD changes in fact evolve over the
course of the disease or whether they behave differentially from other
MRI abnormalities observed in MS, such as brain atrophy or lesion
load.
An unexpected ﬁnding in our study was the lack of correlation
between FD of the GM and GM atrophy, which might have several
explanations. First, GM atrophy is less pronounced in the early stages
of the disease and, because we studied patients with FAMS and RRMS,
we might lack power to detect an association. Second, similarly to the
fact that WM atrophy reduces the extension of WM tissue damage,
GM atrophy might have also precluded the identiﬁcation of GM tissue
damage associated with FD changes.
Our study has some limitations. First, we analyzed patients with
FAMS and RRMS in a cross-sectional study and therefore we cannot
ascertain whether FD changes are more pronounced in progressive
patients, or determine how such changes evolve with disease
duration, or identify the effect of disease-modifying drugs in GM FD
evolution. Secondly, we did not separatelymeasure the FD of deep GM
and cortical GM, which may be affected by different pathological
processes. Third, GM is susceptible to the effect of aging and it is still
not well known how age affects FD of the GM. This aspect is of special
importance when studying patients with progressive forms of the
disease or for prospective studies.
Taking into account that a GM pathology is common in MS [5,15],
the FD increased inMS detected here could be related to an increase in
GM abnormalities, as has been also reported in association with the
irregularities of the GM structure in a FD analysis recently carried out
in schizophrenia [30]. In addition, GM histological abnormalities
increase in MS over time [8], which might account for the signiﬁcant
increase of the FD in the transition from FAMS to RRMS. The
topography of GM damage in MS drives the appearance of functional
deﬁcits [31,32]. We speculate that this might explain why in our study
an overall measurement of GM damage such as FD does not correlate
with disability, which depends on the topography of the brain damage
(i.e. corticospinal pathway for motor function). Localized measure-
ment of FD might provide complimentary information or identifying
more selectively damaged cortical regions, since cortical atrophy does
not appear to be a uniform process throughout the GM [23,33–35].
Cortical damage appears to evolve independently ofWMdamage in
MS [15,36] and our study showing a different behavior of the FD
betweenGMandWMalso supports this concept. Thus, an unanswered
question is whether GM atrophy occurs as a direct result of GM
pathology or whether it is secondary to tissue damage within WM
lesions. The fact that the FD of the GM correlates withWM lesion load,
especially in T1 sequences that are strongly associated with axonal
damage, suggests that at least some of the changes in its architecture is
secondary to axonal damage in the WM. This result agrees with our
previous ﬁnding that axonal damage in the visual radiations explains
up to one third of GM atrophy in some particular regions [37].
However, it can also be argued that this correlation is due to diseasePlease cite this article as: Esteban FJ, et al, Fractal dimension analysis of
jns.2008.12.023activity, meaning that patients with more active disease have more
lesion load in theWM andmore GM abnormalities. On the other hand,
the FD of the GM did not correlate with GM volume, even though we
have detected a decrease of the GM volume in MS; this GM volume
decrease is higher thanpreviously reported [10,11], but this variation in
range may be related to the different processing of the data.
In conclusion, a better understanding of the biological basis of GM
damage is essential in order todevelopnew therapies aimed toprevent
disability accumulation. New neuroimaging and pathological studies
are providing fresh insights into the pathogenesis of GMdamage inMS.
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